PH12014500937A1 - 5-ht 1a receptor substype agonist - Google Patents

5-ht 1a receptor substype agonist

Info

Publication number
PH12014500937A1
PH12014500937A1 PH12014500937A PH12014500937A PH12014500937A1 PH 12014500937 A1 PH12014500937 A1 PH 12014500937A1 PH 12014500937 A PH12014500937 A PH 12014500937A PH 12014500937 A PH12014500937 A PH 12014500937A PH 12014500937 A1 PH12014500937 A1 PH 12014500937A1
Authority
PH
Philippines
Prior art keywords
substype
agonist
receptor
medicament
carbon
Prior art date
Application number
PH12014500937A
Other languages
English (en)
Inventor
Jordan Shaun
Kikuchi Tetsuro
Tottori Katsura
Hirose Tsuyoshi
Uwahodo Yasufumi
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25087808&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PH12014500937(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of PH12014500937A1 publication Critical patent/PH12014500937A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Otolaryngology (AREA)
  • Anesthesiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PH12014500937A 2001-01-29 2014-04-28 5-ht 1a receptor substype agonist PH12014500937A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77021001A 2001-01-29 2001-01-29
PCT/JP2002/000626 WO2002060423A2 (en) 2001-01-29 2002-01-29 Substituted carbostyril derivatives as 5-ht1a receptor subtype agonists

Publications (1)

Publication Number Publication Date
PH12014500937A1 true PH12014500937A1 (en) 2015-09-21

Family

ID=25087808

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12014500937A PH12014500937A1 (en) 2001-01-29 2014-04-28 5-ht 1a receptor substype agonist

Country Status (19)

Country Link
EP (3) EP1712225B1 (https=)
JP (4) JP4178032B2 (https=)
KR (5) KR100713607B1 (https=)
CN (3) CN1239154C (https=)
AR (4) AR032641A1 (https=)
AT (3) ATE504293T1 (https=)
AU (4) AU2002226752C1 (https=)
BR (1) BR0206237A (https=)
CA (2) CA2429496C (https=)
CY (3) CY1105631T1 (https=)
DE (3) DE60220325T2 (https=)
DK (3) DK1712225T3 (https=)
ES (3) ES2261652T3 (https=)
MX (2) MXPA03006603A (https=)
MY (1) MY129355A (https=)
PH (1) PH12014500937A1 (https=)
PT (3) PT1712225E (https=)
TW (2) TWI331919B (https=)
WO (1) WO2002060423A2 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7053092B2 (en) 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
AR032641A1 (es) * 2001-01-29 2003-11-19 Otsuka Pharma Co Ltd Agonista de subtipo de receptor 5-ht 1a.
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
US8703772B2 (en) 2001-09-25 2014-04-22 Otsuka Pharmaceutical Co., Ltd. Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
DE10148233A1 (de) * 2001-09-28 2003-04-10 Boehringer Ingelheim Pharma Verbindungen zur Reduzierung übermäßiger Nahrungsaufnahme
CA2529857A1 (en) * 2002-07-30 2004-02-05 Peter Migaly Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions
KR100842694B1 (ko) * 2002-12-27 2008-07-01 오쓰까 세이야꾸 가부시키가이샤 기분 장애 치료용 카르보스티릴 유도체 및 세로토닌 재흡수억제제
AR042806A1 (es) * 2002-12-27 2005-07-06 Otsuka Pharma Co Ltd Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo
GEP20084567B (en) * 2003-05-23 2008-12-25 Otsuka Pharma Co Ltd Carbostyril derivatives and mood stabilizers for treating mood disorders
US7160888B2 (en) * 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
FR2865650B1 (fr) * 2004-01-30 2008-06-13 Biocortech Utilisation du 14,15 dihydro 20,21-dinoreburnamenin14-ol pour traiter et/ou prevenir les depressions majeures et les desordres du cycle veille-sommeil
WO2006090273A2 (en) * 2005-02-22 2006-08-31 Warner-Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds with keto or hydroxyl linkers for the treatment of schizophrenia
JP2009503020A (ja) * 2005-08-03 2009-01-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 肥満症の治療におけるフリバンセリンの使用
TW200848041A (en) 2007-03-30 2008-12-16 Otsuka Pharma Co Ltd A medicament for treating schizophrenia comprising cilostazol
GB2456183A (en) 2008-01-04 2009-07-08 Gw Pharma Ltd Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
JP2009286740A (ja) * 2008-05-30 2009-12-10 Otsuka Pharmaceut Co Ltd アリピプラゾールを含有する逆耐性抑制剤
EP2338873A1 (en) 2009-12-22 2011-06-29 Gmeiner, Peter New aminotetraline derivatives
TW201343201A (zh) 2012-03-06 2013-11-01 Otsuka Pharma Co Ltd 持續釋放型口服固體製劑
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54130587A (en) * 1978-03-30 1979-10-09 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
JPS5646812A (en) * 1979-09-27 1981-04-28 Otsuka Pharmaceut Co Ltd Central nervous system depressant
DE3721799C2 (de) 1986-07-01 1993-12-23 Mitsubishi Electric Corp Integrierte Redox-Bauelementschaltung und Verfahren zum Herstellen
JP2608788B2 (ja) * 1988-10-31 1997-05-14 大塚製薬 株式会社 精神分裂病治療剤
US5006528A (en) * 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
JP3155276B2 (ja) * 1991-05-20 2001-04-09 ファルマシア・アンド・アップジョン・カンパニー カルボキサミド−（１，２ｎ）−カルボサイクリック−２−アミノテトラリン誘導体
US5532240A (en) * 1991-12-26 1996-07-02 Yoshitomi Pharmaceutical Industries, Ltd. Condensed thiophene compound and pharmaceutical use thereof
WO1994009765A1 (en) * 1992-10-23 1994-05-11 New York University Functional interactions between glial s-100b and central nervous system serotonergic neurons
DK148292D0 (da) * 1992-12-09 1992-12-09 Lundbeck & Co As H Forbindelser
JP2959615B2 (ja) * 1993-06-24 1999-10-06 吉富製薬株式会社 縮合型チオフェン化合物およびその医薬用途
JPH09291034A (ja) * 1996-02-27 1997-11-11 Yoshitomi Pharmaceut Ind Ltd 縮合ピリジン化合物およびその医薬としての用途
US5688950A (en) * 1996-04-23 1997-11-18 Neurogen Corporation Tricyclic aminoalkylcarboxamides; novel dopamine D3 receptor subtype specific ligands
DK0904273T3 (da) * 1996-05-07 2003-07-07 Pfizer Mesylat-trihydratsalt af 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl-6-chlor-1,3-dihydro-2(1H)-indol-2-on(=ziprasidon), dets fremstilling og dets anvendelse som dipamin D2 antagonist
JP4012994B2 (ja) * 1996-05-08 2007-11-28 大塚製薬株式会社 抗不安薬
CA2264080A1 (en) * 1996-08-27 1998-03-05 Richard Eric Mewshaw 4-aminoethoxy indoles as dopamin d2 agonists and as 5ht1a ligands
CN1289333A (zh) * 1998-02-03 2001-03-28 美国家用产品公司 用作血清素－1a受体激动剂的噁唑衍生物
ZA992670B (en) * 1998-04-13 2000-10-12 American Home Prod 4-amino-(ethylamino)-oxindole dopamine autoreceptor agonists.
JPH11335286A (ja) * 1998-05-25 1999-12-07 Mitsui Chem Inc ドーパミン拮抗薬の効果増強剤
AR032641A1 (es) * 2001-01-29 2003-11-19 Otsuka Pharma Co Ltd Agonista de subtipo de receptor 5-ht 1a.
EP1397145B1 (en) * 2001-06-19 2006-09-06 Norbert Müller Use of cox-2 inhibitors for the treatment of schizophrenia, or tic disorders
AR033485A1 (es) * 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma

Also Published As

Publication number Publication date
ES2286755T3 (es) 2007-12-01
WO2002060423A2 (en) 2002-08-08
AU2005201772C1 (en) 2010-06-03
DE60220325D1 (de) 2007-07-05
CA2700314C (en) 2012-04-24
DK1355639T3 (da) 2006-08-14
AU2007201701B2 (en) 2010-06-17
PT1712225E (pt) 2011-04-18
CY1111392T1 (el) 2015-08-05
CA2700314A1 (en) 2002-08-08
TW200522960A (en) 2005-07-16
BR0206237A (pt) 2003-12-23
WO2002060423A3 (en) 2003-04-10
CY1108031T1 (el) 2013-09-04
TWI302832B (en) 2008-11-11
MY129355A (en) 2007-03-30
EP1621198A3 (en) 2006-04-12
AU2002226752C1 (en) 2010-02-18
KR100825705B1 (ko) 2008-04-29
ATE322894T1 (de) 2006-04-15
KR20060085260A (ko) 2006-07-26
JP2007297405A (ja) 2007-11-15
CN1813745A (zh) 2006-08-09
KR20030065570A (ko) 2003-08-06
EP1355639A2 (en) 2003-10-29
CY1105631T1 (el) 2010-12-22
PT1621198E (pt) 2007-06-08
DK1712225T3 (da) 2011-06-20
HK1061805A1 (en) 2004-10-08
DE60220325T2 (de) 2008-01-17
EP1621198B1 (en) 2007-05-23
EP1355639B1 (en) 2006-04-12
ES2261652T3 (es) 2006-11-16
EP1621198A2 (en) 2006-02-01
CN1239154C (zh) 2006-02-01
EP1712225B1 (en) 2011-04-06
DE60239711D1 (de) 2011-05-19
AU2009233591A1 (en) 2009-11-19
AU2002226752B2 (en) 2005-03-17
CN1484524A (zh) 2004-03-24
JP4896831B2 (ja) 2012-03-14
KR100653591B1 (ko) 2006-12-05
AR099754A2 (es) 2016-08-17
CA2429496C (en) 2010-10-19
AR032641A1 (es) 2003-11-19
ES2363366T3 (es) 2011-08-02
DE60210581T2 (de) 2007-04-05
AU2005201772A1 (en) 2005-05-19
MX344556B (es) 2016-12-20
CA2429496A1 (en) 2002-08-08
KR20050107822A (ko) 2005-11-15
KR20060028485A (ko) 2006-03-29
JP4178032B2 (ja) 2008-11-12
ATE504293T1 (de) 2011-04-15
AU2005201772B2 (en) 2007-05-17
KR100763288B1 (ko) 2007-10-04
JP2011225587A (ja) 2011-11-10
KR100713607B1 (ko) 2007-05-02
JP2004517937A (ja) 2004-06-17
KR100601073B1 (ko) 2006-07-19
AR080849A2 (es) 2012-05-09
ATE362763T1 (de) 2007-06-15
EP1712225A1 (en) 2006-10-18
AU2007201701A1 (en) 2007-05-10
JP2011184460A (ja) 2011-09-22
DK1621198T3 (da) 2007-09-24
TWI331919B (en) 2010-10-21
JP5683010B2 (ja) 2015-03-11
DE60210581D1 (en) 2006-05-24
HK1091403A1 (zh) 2007-01-19
AR079761A2 (es) 2012-02-15
AU2009233591B2 (en) 2011-10-20
CN1879624A (zh) 2006-12-20
MXPA03006603A (es) 2004-02-12
KR20070065425A (ko) 2007-06-22
CN100450485C (zh) 2009-01-14
PT1355639E (pt) 2006-06-30

Similar Documents

Publication Publication Date Title
PH12014500937A1 (en) 5-ht 1a receptor substype agonist
SE0302760D0 (sv) New compounds
MXPA04002338A (es) Derivados de carbazol y su uso como antagonistas receptores del npy5.
MXPA04005209A (es) Antagonistas del receptor de adenosina a2a.
MXPA02012712A (es) N-ureidoheterocicloalquil-piperidinas como moduladores de la actividad del receptor de quimiocinas.
AP2002002664A0 (en) Cyclohexylamine derivative as subtype selective NMDA receptor antagonists.
TW200517388A (en) Thiazole derivatives as cannabinoid receptor modulators
PL343771A1 (en) N-substituted aminotetralins as ligands for the neuropeptide y y5 receptor useful in the treatment of obesity and other disorders
EE200300403A (et) N-asendatud mittearomaatne heterotsükliline ühend, seda sisaldav ravimkompositsioon ning ühendi kasutamine ravimina
MY141559A (en) Triazole derivatives as tachykinin receptor antagonists
MXPA04003439A (es) Compuestos de maleimida 3,4 disustituidos como antagonistas de receptor de quimiocina cxc.
WO2003048164A3 (en) Adenosine a2a receptor antagonists
PL1735278T3 (pl) Związki receptora histaminowego H3, wytwarzanie i zastosowania terapeutyczne
EA200601194A1 (ru) Новые производные бензофурана, используемые для профилактики или лечения нарушений, связанных с 5-ht-рецептором
MX2008001606A (es) Piperazinas substituidas como antagonistas de receptor de glutamato metabotropico.
IL159880A0 (en) Arylsulfonyl derivatives with 5-ht6 receptor affinity
CA2354606A1 (en) Azabicycloalkane derivatives and therapeutic uses thereof
TW200631956A (en) Azabenzoxazoles for the treatment of CNS disorders
UA81640C2 (ru) Противомикобактериальные соединения, способ их получения, фармацевтическая композиция на их основе
NO20080671L (no) Bisykliske piperaziner som metabotrofiske glutamatreseptorantagonister
MY142739A (en) Carbostyril derivatives for accelerating salivation
UA83870C2 (ru) Замещенные бицикло[3.1.1]гептаном производные бензимидазолона и хиназолинона как агонисты человеческих рецепторов orl1
WO2002024661A3 (en) New n, n'-disubstituted benzimidazolone derivatives with affinity at the serotonin and dopamine receptors
MX2022004213A (es) Derivados de 2-azaspiro[3.4]octano como agonistas de m4.
CA2490002A1 (en) Novel tetracyclic arylcarbonyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them